CARgenix Holdings Overview

  • Founded
  • 2015
  • Status
  • Acquired/​Merged
  • Employees
  • 11
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

CARgenix Holdings General Information


Owner and operator of a pharmaceutical company. The company is engaged in providing services related to discovery, development, and delivery of chimeric antigen receptor (CAR) T-cell immunotherapies.

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
TNK Therapeutics
Primary Office
  • 199 Grotto Avenue
  • Providence, RI 02906
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CARgenix Holdings Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CARgenix Holdings‘s full profile, request access.

Request a free trial

CARgenix Holdings Executive Team (1)

Name Title Board Seat Contact Info
Jaymin Patel Manager
To view CARgenix Holdings’s complete executive team members history, request access »

CARgenix Holdings Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial